Cevimeline Side Effects
Brand Names: Evoxac
Please note - some side effects for Cevimeline may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects of Cevimeline - for the Consumer
Cevimeline
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Cevimeline:
Seek medical attention right away if any of these SEVERE side effects occur when using Cevimeline:Blurred vision; coughing; hot flashes; joint pain; nausea; stuffy nose; sweating; tiredness; trouble sleeping.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); abdominal pain; breathing problems; chest pain; confusion; diarrhea; excessive saliva; excessive sweating; excessive tears; fast, slow, or irregular heartbeat; fever, chills, or sore throat; headache; increased or painful urination; severe nausea or vomiting; severe or persistent stomach pain; tremors; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
TopSide Effects by Body System - for Healthcare Professionals
Nervous system
Nervous system side effects have included excess sweating (19%) and excessive salivation (2%).
Gastrointestinal
Gastrointestinal side effects have included nausea (14%), diarrhea (10%), dyspepsia (8%), abdominal pain (8%), vomiting (4.6%) and cholecystitis.
General
General side effects have included headache (14%), injury (5%), dizziness (4%), surgical intervention (3%), fatigue (3%), pain (3%), hot flushes (2%), and insomnia (2%).
Respiratory
Respiratory side effects have included sinusitis (12%), upper respiratory tract infection (11%), rhinitis (11%), coughing (6%), pharyngitis (5%), and bronchitis (4%).
Genitourinary
Genitourinary side effects have included urinary tract infection (6%) and urinary frequency (1%).
Musculoskeletal
Musculoskeletal side effects have included back pain (5%), arthralgia (4%), skeletal pain (3%), and rigors (1%).
Dermatologic
Dermatologic side effects have included rash (4%).
Ocular
Ocular side effects have included conjunctivitis (4%).
Hepatic
Hepatic side effects including liver and biliary systems disorders and cholecystitis have been reported.
TopMore Cevimeline resources
- cevimeline Concise Consumer Information (Cerner Multum)
- cevimeline Advanced Consumer (Micromedex) - Includes Dosage Information
- Cevimeline MedFacts Consumer Leaflet (Wolters Kluwer)
- Cevimeline Hydrochloride Monograph (AHFS DI)
- Evoxac Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
